Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Evaluation the TECNIS IOL in Both Eyes VS the ReZoom IOL in One and TECNIS IOL in the Opposite
A Retrospective Evaluation Comparing Post Operative Visual Outcomes in Patients Implanted With the TECNIS IOL in Both Eyes Versus the ReZoom IOL in One Eye and TECNIS IOL in the Opposite Eye
Status: Enrolling
Updated:  1/24/2013
Bucci Laser Vision Institute
mi
from
Wilkes-Barre, PA
Evaluation the TECNIS IOL in Both Eyes VS the ReZoom IOL in One and TECNIS IOL in the Opposite
A Retrospective Evaluation Comparing Post Operative Visual Outcomes in Patients Implanted With the TECNIS IOL in Both Eyes Versus the ReZoom IOL in One Eye and TECNIS IOL in the Opposite Eye
Status: Enrolling
Updated: 1/24/2013
Bucci Laser Vision Institute
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age
Status: Enrolling
Updated:  1/24/2013
Bausch & Lomb Incorporated
mi
from
Rochester, NY
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age
Status: Enrolling
Updated: 1/24/2013
Bausch & Lomb Incorporated
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
Status: Enrolling
Updated:  1/24/2013
Durrie Vision
mi
from
Overland Park, KA
Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
Status: Enrolling
Updated: 1/24/2013
Durrie Vision
mi
from
Overland Park, KA
Click here to add this to my saved trials
Visual Outcomes and Contrast Sensitivity After Myopic LASIK
Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser
Status: Enrolling
Updated:  1/25/2013
Durrie Vision
mi
from
Overland Park, KA
Visual Outcomes and Contrast Sensitivity After Myopic LASIK
Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser
Status: Enrolling
Updated: 1/25/2013
Durrie Vision
mi
from
Overland Park, KA
Click here to add this to my saved trials
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated:  2/7/2013
Contact Hoya Surgical Optics, Inc. for Trial Locations
mi
from
Chino Hills, CA
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated: 2/7/2013
Contact Hoya Surgical Optics, Inc. for Trial Locations
mi
from
Chino Hills, CA
Click here to add this to my saved trials
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated:  2/7/2013
Shepard Eye Center
mi
from
Santa Maria, CA
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated: 2/7/2013
Shepard Eye Center
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated:  2/7/2013
Mid-Florida Eye Center
mi
from
Mt. Dora, FL
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated: 2/7/2013
Mid-Florida Eye Center
mi
from
Mt. Dora, FL
Click here to add this to my saved trials
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated:  2/7/2013
Grosinger, Spigelman & Grey,
mi
from
Bloomfield Hills, MI
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated: 2/7/2013
Grosinger, Spigelman & Grey,
mi
from
Bloomfield Hills, MI
Click here to add this to my saved trials
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated:  2/7/2013
Silverstein Eye Conters
mi
from
Dansas City, MO
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated: 2/7/2013
Silverstein Eye Conters
mi
from
Dansas City, MO
Click here to add this to my saved trials
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated:  2/7/2013
Cleveland Eye Clinic
mi
from
Breckville, OH
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses
Status: Enrolling
Updated: 2/7/2013
Cleveland Eye Clinic
mi
from
Breckville, OH
Click here to add this to my saved trials
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Status: Enrolling
Updated:  2/11/2013
Pacific Eye Associates
mi
from
San Francisco, CA
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Status: Enrolling
Updated: 2/11/2013
Pacific Eye Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Status: Enrolling
Updated:  2/11/2013
Retina Associates of Kentucky
mi
from
Lexington, KY
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Status: Enrolling
Updated: 2/11/2013
Retina Associates of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Status: Enrolling
Updated:  2/11/2013
Tennessee Retina, P.C.
mi
from
Nashville, TN
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Status: Enrolling
Updated: 2/11/2013
Tennessee Retina, P.C.
mi
from
Nashville, TN
Click here to add this to my saved trials
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
Diabetic Macular Edema and Diabetic Retinopathy Identification by Screening (Telemed) With Verified Automated Retinal Photography
Status: Enrolling
Updated:  2/12/2013
Craig Kadooka, MD
mi
from
Hilo, HI
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
Diabetic Macular Edema and Diabetic Retinopathy Identification by Screening (Telemed) With Verified Automated Retinal Photography
Status: Enrolling
Updated: 2/12/2013
Craig Kadooka, MD
mi
from
Hilo, HI
Click here to add this to my saved trials
ESBA1008 Safety, Tolerability and Effects in Wet Age-related Macular Degeneration (AMD) Patients
Status: Enrolling
Updated:  2/18/2013
Alcon Call Center
mi
from
Fort Worth, TX
ESBA1008 Safety, Tolerability and Effects in Wet Age-related Macular Degeneration (AMD) Patients
Status: Enrolling
Updated: 2/18/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration
Status: Enrolling
Updated:  2/20/2013
Massachussetts Eye & Ear Infirmary
mi
from
Boston, MA
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration
Status: Enrolling
Updated: 2/20/2013
Massachussetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
Status: Enrolling
Updated:  2/21/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
Status: Enrolling
Updated: 2/21/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%
Status: Enrolling
Updated:  2/27/2013
University of Iowa
mi
from
Iowa City, IA
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%
Status: Enrolling
Updated: 2/27/2013
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients
Status: Enrolling
Updated:  3/4/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients
Status: Enrolling
Updated: 3/4/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  3/6/2013
Bausch & Lomb Incorporated
mi
from
Rochester, NY
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 3/6/2013
Bausch & Lomb Incorporated
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration
Status: Enrolling
Updated:  3/7/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration
Status: Enrolling
Updated: 3/7/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Home Vision Monitoring in AREDS2 for Progression to Neovascular Age-Related Macular Degeneration
Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the Foresee Home Device
Status: Enrolling
Updated:  3/14/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Home Vision Monitoring in AREDS2 for Progression to Neovascular Age-Related Macular Degeneration
Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the Foresee Home Device
Status: Enrolling
Updated: 3/14/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers
Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers Using a Schirmer Strip for Tear Collection
Status: Enrolling
Updated:  3/15/2013
Bausch & Lomb Incorporated
mi
from
Rochester, NY
Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers
Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers Using a Schirmer Strip for Tear Collection
Status: Enrolling
Updated: 3/15/2013
Bausch & Lomb Incorporated
mi
from
Rochester, NY
Click here to add this to my saved trials
A Comparison of Infection Rates Between Two Surgical Sites
A Comparative Assessment Between Two Surgical Sites of the Rate of Corneal Toxicity and Ototoxicity With the Use of Povidone-iodine Versus Chlorhexidine-alcohol for Facial Lesions Treated With Mohs Micrographic Surgery
Status: Enrolling
Updated:  3/18/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
A Comparison of Infection Rates Between Two Surgical Sites
A Comparative Assessment Between Two Surgical Sites of the Rate of Corneal Toxicity and Ototoxicity With the Use of Povidone-iodine Versus Chlorhexidine-alcohol for Facial Lesions Treated With Mohs Micrographic Surgery
Status: Enrolling
Updated: 3/18/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Effects of Anti-Glaucoma Medications on the Ocular Surface
In Vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study
Status: Enrolling
Updated:  3/20/2013
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Effects of Anti-Glaucoma Medications on the Ocular Surface
In Vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study
Status: Enrolling
Updated: 3/20/2013
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Systane Family - Meibomian Deficiency
Systane Family Efficacy in Meibomian Gland Functionality for Lipid Deficient Evaporative Dry Eye Subjects
Status: Enrolling
Updated:  3/27/2013
Alcon Call Center
mi
from
Fort Worth, TX
Systane Family - Meibomian Deficiency
Systane Family Efficacy in Meibomian Gland Functionality for Lipid Deficient Evaporative Dry Eye Subjects
Status: Enrolling
Updated: 3/27/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Status: Enrolling
Updated:  4/1/2013
Alcon Call Center
mi
from
Fort Worth, TX
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Status: Enrolling
Updated: 4/1/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Kenneth Sall, M.D.
mi
from
Artesia, CA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Kenneth Sall, M.D.
mi
from
Artesia, CA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
United Medical Research Institute
mi
from
Inglewood, CA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
United Medical Research Institute
mi
from
Inglewood, CA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Aesthetic Eye Care Institute
mi
from
Newport Beach, CA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Aesthetic Eye Care Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Bacharach practice
mi
from
Petaluma, CA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Bacharach practice
mi
from
Petaluma, CA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Centre For Health Care
mi
from
Poway, CA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Centre For Health Care
mi
from
Poway, CA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Clayton Eye Center
mi
from
Morrow, GA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Coastal Research Associates, LLC
mi
from
Roswell, GA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Coastal Research Associates, LLC
mi
from
Roswell, GA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Bradley Kwapiszeski, MD
mi
from
Shawnee Mission, KA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Bradley Kwapiszeski, MD
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Taustine Eye Center
mi
from
Louisville, KY
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Taustine Eye Center
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Alan L. Robin, MD, PA
mi
from
Baltimore, MD
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Alan L. Robin, MD, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Seidenberg Protzko Eye Associates
mi
from
Havre de Grace, MD
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Seidenberg Protzko Eye Associates
mi
from
Havre de Grace, MD
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Great Lakes Eye Care
mi
from
St. Joseph, MI
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Great Lakes Eye Care
mi
from
St. Joseph, MI
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Jeffrey Schultz, M.D.
mi
from
Bronx, NY
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Jeffrey Schultz, M.D.
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Ophthalmic Consultants of Long Island
mi
from
Lynbrook, NY
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Ophthalmic Consultants of Long Island
mi
from
Lynbrook, NY
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Rochester Ophthalmological Group
mi
from
Rochester, NY
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Rochester Ophthalmological Group
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
The Eye Institute
mi
from
Tulsa, OK
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
The Eye Institute
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Texan Eye
mi
from
Austin, TX
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Texan Eye
mi
from
Austin, TX
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Medical Center Ophth. Associates
mi
from
San Antonio, TX
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Medical Center Ophth. Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Stacy R. Smith, M.D.
mi
from
Salt Lake City, UT
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Stacy R. Smith, M.D.
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated:  4/8/2013
Virginia Eye Consultants
mi
from
Norfolk, VA
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
Status: Enrolling
Updated: 4/8/2013
Virginia Eye Consultants
mi
from
Norfolk, VA
Click here to add this to my saved trials
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Collection of Whole Blood Specimens and Buccal Swabs From Subjects Diagnosed With CNV AMD, Dry AMD, and Age-Matched Controls to Assess the Association of Genetic Variants in Complement Factor H With Risk of Progression to CNV.
Status: Enrolling
Updated:  4/10/2013
Morris Eye Group
mi
from
Encinitas, CA
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Collection of Whole Blood Specimens and Buccal Swabs From Subjects Diagnosed With CNV AMD, Dry AMD, and Age-Matched Controls to Assess the Association of Genetic Variants in Complement Factor H With Risk of Progression to CNV.
Status: Enrolling
Updated: 4/10/2013
Morris Eye Group
mi
from
Encinitas, CA
Click here to add this to my saved trials
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  4/10/2013
Elman Retina Group, PA
mi
from
Baltimore, MD
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 4/10/2013
Elman Retina Group, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials